Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MASI 
Masimo Corporation (MASI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/30/2025: MASI (4-star) is a STRONG-BUY. BUY since 2 days. Profits (2.31%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 63.61% | Avg. Invested days 45 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.06B USD | Price to earnings Ratio - | 1Y Target Price 193.76 |
Price to earnings Ratio - | 1Y Target Price 193.76 | ||
Volume (30-day avg) 504102 | Beta 1.03 | 52 Weeks Range 101.61 - 194.88 | Updated Date 04/1/2025 |
52 Weeks Range 101.61 - 194.88 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.56% | Operating Margin (TTM) -9.09% |
Management Effectiveness
Return on Assets (TTM) 0.61% | Return on Equity (TTM) -25.23% |
Valuation
Trailing PE - | Forward PE 40 | Enterprise Value 9725342888 | Price to Sales(TTM) 4.32 |
Enterprise Value 9725342888 | Price to Sales(TTM) 4.32 | ||
Enterprise Value to Revenue 4.64 | Enterprise Value to EBITDA 29.56 | Shares Outstanding 54035200 | Shares Floating 44887553 |
Shares Outstanding 54035200 | Shares Floating 44887553 | ||
Percent Insiders 7.77 | Percent Institutions 99.48 |
Analyst Ratings
Rating 4.11 | Target Price 178.51 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Masimo Corporation
Company Overview
History and Background
Masimo Corporation was founded in 1989 by Joe Kiani. It initially focused on developing signal processing technologies to improve the accuracy of pulse oximetry. Over time, it expanded into other noninvasive patient monitoring solutions.
Core Business Areas
- Healthcare: Develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, including pulse oximetry, capnography, and brain monitoring.
- Connected Care: Develops technologies related to automation, interoperability, and connectivity of patient data.
- Audio: In 2022, Masimo acquired Sound United, which has brands such as Bowers & Wilkins, Denon, and Marantz. The audio business segment focuses on high-end audio equipment and solutions. This segment has had headwinds for Masimo.
Leadership and Structure
Joe Kiani is the Chairman and CEO. The company has a board of directors and a management team overseeing various functional areas.
Top Products and Market Share
Key Offerings
- Product Name 1: Radical-7 Pulse CO-Oximeter: A noninvasive patient monitoring device that measures multiple blood constituents and physiological parameters. Masimo has a significant market share in pulse oximetry, estimated at around 25%. Competitors include Medtronic and Philips Healthcare.
- Product Name 2: ISA Capnography: Measures carbon dioxide levels in exhaled breath. Masimo is a major player in this market. Competitors include Medtronic and Philips Healthcare.
- Product Name 3: Root Patient Monitoring and Connectivity Platform: A versatile, expandable hub that allows clinicians to simultaneously monitor and assess multiple parameters. Competitors include GE Healthcare and Siemens Healthineers.
Market Dynamics
Industry Overview
The patient monitoring market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements. It's competitive with consolidation occurring.
Positioning
Masimo is positioned as an innovator in noninvasive patient monitoring with proprietary technologies like SET pulse oximetry. Its competitive advantages include accuracy, reliability, and a broad product portfolio. However, the audio segment is a drag on performance.
Total Addressable Market (TAM)
The global patient monitoring market is estimated to be in the tens of billions of dollars. Masimo is addressing this TAM through its core patient monitoring products and expansion into new areas such as connected care and consumer audio. However, expansion into consumer audio via the Sound United acquisition has been a distraction.
Upturn SWOT Analysis
Strengths
- Proprietary SET pulse oximetry technology
- Strong brand reputation for accuracy and reliability
- Broad product portfolio
- Global presence
- Innovation in non-invasive monitoring
Weaknesses
- Dependence on hospital capital spending
- Competition from larger medical device companies
- Integration challenges with acquisitions (Sound United)
- Performance of the audio business segment
Opportunities
- Expanding into emerging markets
- Developing new noninvasive monitoring technologies
- Leveraging connected care solutions
- Partnerships with other healthcare providers
- Growth in home healthcare
Threats
- Increased competition
- Pricing pressures
- Technological obsolescence
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- MDT
- PHG
- GE
Competitive Landscape
Masimo has a strong position in niche areas of patient monitoring. Its competitive advantages stem from its proprietary technology, but it faces challenges from larger, diversified medical device companies.
Major Acquisitions
Sound United
- Year: 2022
- Acquisition Price (USD millions): 1025
- Strategic Rationale: Masimo acquired Sound United to expand into the consumer audio market and leverage its signal processing technologies. However, this acquisition has led to investor concerns about diversification and management focus.
Growth Trajectory and Initiatives
Historical Growth: Masimo has historically grown through organic innovation and acquisitions, though the Sound United acquisition is underperforming. Growth in the patient monitoring segment has been consistent.
Future Projections: Future growth projections depend on analyst estimates and market conditions.
Recent Initiatives: Recent initiatives include new product launches in patient monitoring and efforts to integrate Sound United.
Summary
Masimo Corporation is a leading innovator in noninvasive patient monitoring, driven by its proprietary technologies. However, it's currently facing challenges from the underperforming Sound United acquisition and increased competition. Its core business remains strong, but the audio segment needs significant improvement. Growth opportunities exist in emerging markets and connected care.
Similar Companies
- MDT
- GE
- HON
- SIXT
- COTY
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change. Numerical data may be estimates and subject to revision. Data on financial performance is for illustrative purposes only and is not current.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Masimo Corporation
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2007-08-08 | CEO & Director Ms. Catherine M. Szyman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3600 | Website https://www.masimo.com |
Full time employees 3600 | Website https://www.masimo.com | ||
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, methemoglobin, hemoglobin, fractional arterial oxygen saturation, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow respiratory support therapy, neuromodulation technology, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.